Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by U.S. Capital Wealth Advisors LLC

Posted by Defense World Staff on Apr 30th, 2023

U.S. Capital Wealth Advisors LLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) by 95.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 600 shares of the medical equipment provider’s stock after selling 14,034 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $76,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Crossmark Global Holdings Inc. raised its holdings in Zimmer Biomet by 0.7% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 14,006 shares of the medical equipment provider’s stock valued at $1,464,000 after acquiring an additional 91 shares during the last quarter. HB Wealth Management LLC raised its holdings in Zimmer Biomet by 4.0% in the 4th quarter. HB Wealth Management LLC now owns 2,371 shares of the medical equipment provider’s stock valued at $302,000 after acquiring an additional 92 shares during the last quarter. Creative Financial Designs Inc. ADV raised its holdings in Zimmer Biomet by 21.3% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 563 shares of the medical equipment provider’s stock valued at $59,000 after acquiring an additional 99 shares during the last quarter. Securian Asset Management Inc. increased its holdings in shares of Zimmer Biomet by 0.6% during the 4th quarter. Securian Asset Management Inc. now owns 17,176 shares of the medical equipment provider’s stock worth $2,190,000 after buying an additional 100 shares during the last quarter. Finally, Farmers & Merchants Investments Inc. increased its holdings in shares of Zimmer Biomet by 5.8% during the 3rd quarter. Farmers & Merchants Investments Inc. now owns 1,860 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 102 shares during the last quarter. 87.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In related news, VP Chad F. Phipps sold 23,045 shares of the stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $124.50, for a total transaction of $2,869,102.50. Following the sale, the vice president now owns 43,671 shares in the company, valued at $5,437,039.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ZBH. Loop Capital upped their price objective on Zimmer Biomet from $125.00 to $140.00 in a report on Monday, February 6th. Jefferies Financial Group upgraded Zimmer Biomet from an “underperform” rating to a “hold” rating and upped their price objective for the stock from $115.00 to $130.00 in a report on Friday, March 31st. Oppenheimer upped their price objective on Zimmer Biomet from $120.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, February 6th. UBS Group began coverage on Zimmer Biomet in a report on Tuesday, March 28th. They set a “sell” rating and a $112.00 price objective for the company. Finally, Robert W. Baird upped their price objective on Zimmer Biomet from $133.00 to $145.00 in a report on Monday, February 6th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $134.19.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $138.44 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.88 and a quick ratio of 0.97. The firm has a 50-day moving average of $128.38 and a two-hundred day moving average of $123.25. The stock has a market cap of $28.93 billion, a P/E ratio of 125.85, a PEG ratio of 3.17 and a beta of 1.00. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.39 and a 1-year high of $140.29.

Zimmer Biomet (NYSE:ZBH – Get Rating) last issued its quarterly earnings results on Friday, February 3rd. The medical equipment provider reported $1.88 EPS for the quarter, topping the consensus estimate of $1.83 by $0.05. Zimmer Biomet had a net margin of 3.33% and a return on equity of 11.97%. The business had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.76 billion. During the same quarter last year, the company posted $1.95 earnings per share. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.04 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 28th. Stockholders of record on Wednesday, March 29th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, March 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.69%. Zimmer Biomet’s payout ratio is 87.27%.

Zimmer Biomet Company Profile

(Get Rating)

Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.